Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

Inclusion Criteria: * PATIENTS WITH BRONJ: * All cancer patients \> 18 years of any ethnicity who have been treated with intravenous zoledronate (zoledronic acid) for \>=1 year duration * Clinical diagnosis of BRONJ subsequent to oral surgery as established by standard clinical protocol per American Association of Oral and Maxillofacial Surgeons (AAOMS) diagnostic criteria * Willingness to have photographs taken to document lesions * Consent for sample collection for urine, hematology, histopathology and microbial profiling * Cognitively able and willing to provide consent * Have a World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance score =\< 2 and life expectancy \> 6 months * PATIENTS WITHOUT BRONJ: * Cancer patients without BRONJ who have been treated with intravenous zoledronate for \>= 1 year duration * No signs or symptoms of BRONJ * Willingness to provide consent for sample collection for blood, urine and saliva Exclusion Criteria: * WHO/ECOG performance score \> 2 and life expectancy of \< 6 months * Coagulopathy * Active systemic infection or autoimmune disease * Currently pregnant or within 3 months post-partum, or unwilling to undergo pregnancy testing or report possible pregnancy promptly * Severe cardiovascular, pulmonary or other systemic conditions that prevent participation in the study * Salivary gland hypofunction regardless of underlying pathology * Neutropenia (serum absolute neutrophil count \[ANC\] \< 1,000/uL) * Cognitive, language or hearing problems * Renal disease, and we will use a calculated serum creatinine clearance over 30 ml/min at the screening appointment as an exclusion criteria * Participation in another research project that might interfere with completion of this study * Patients undergoing active antibiotic therapy